semaglutide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
glucagon-like peptide (GLP) analogues and agonists 5267 910463-68-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • rybelsus
  • semaglutide
  • NNC 0113-0217
  • ozempic
  • wegovy
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.
  • Molecular weight: 4113.64
  • Formula: C187H291N45O59
  • CLOGP:
  • LIPINSKI: None
  • HAC: 104
  • HDO: 57
  • TPSA: 1646.18
  • ALOGS:
  • ROTB: 149

Drug dosage:

DoseUnitRoute
10.50 mg O
0.11 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Feb. 8, 2018 EMA Novo Nordisk A/S
Dec. 5, 2017 FDA NOVO NORDISK INC
March 23, 2018 PMDA Novo Nordisk Pharma Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pancreatitis 438.02 16.13 222 15394 48833 63424573
Nausea 380.22 16.13 716 14900 853755 62619651
Diabetic ketoacidosis 304.50 16.13 132 15484 20373 63453033
Vomiting 264.85 16.13 483 15133 559134 62914272
Euglycaemic diabetic ketoacidosis 143.65 16.13 48 15568 3626 63469780
Weight decreased 121.39 16.13 232 15384 276566 63196840
Blood glucose increased 110.61 16.13 119 15497 83637 63389769
Glycosylated haemoglobin increased 95.78 16.13 51 15565 12347 63461059
Inappropriate schedule of product administration 85.24 16.13 116 15500 103849 63369557
Heart sounds 81.73 16.13 23 15593 973 63472433
Prolonged expiration 79.55 16.13 23 15593 1073 63472333
Sleep disorder due to a general medical condition 77.25 16.13 44 15572 12144 63461262
Pancreatic carcinoma 75.24 16.13 37 15579 7591 63465815
COVID-19 74.85 16.13 114 15502 112989 63360417
Cholelithiasis 73.60 16.13 71 15545 43854 63429552
Decreased appetite 72.63 16.13 178 15438 250874 63222532
Drug dose titration not performed 70.34 16.13 18 15598 527 63472879
Ketoacidosis 67.61 16.13 29 15587 4349 63469057
Drug titration error 67.51 16.13 19 15597 804 63472602
Retinopathy 66.39 16.13 26 15590 3093 63470313
Diarrhoea 66.25 16.13 348 15268 715018 62758388
Dehydration 65.83 16.13 137 15479 173217 63300189
Blood glucose decreased 64.33 16.13 48 15568 20904 63452502
Diabetic retinopathy 62.54 16.13 23 15593 2304 63471102
Thyroid mass 61.81 16.13 27 15589 4231 63469175
Lipase increased 60.76 16.13 35 15581 9865 63463541
Product communication issue 57.17 16.13 16 15600 663 63472743
Depressive symptom 56.28 16.13 25 15591 4077 63469329
Eructation 55.28 16.13 31 15585 8302 63465104
Drug ineffective 55.20 16.13 109 15507 1044656 62428750
Product dispensing error 54.26 16.13 33 15583 10272 63463134
Off label use 53.60 16.13 315 15301 674147 62799259
Flank pain 51.28 16.13 38 15578 16372 63457034
Myoglobinuria 49.18 16.13 12 15604 288 63473118
Mesenteric panniculitis 48.29 16.13 10 15606 110 63473296
Hypoglycaemia 46.15 16.13 65 15551 60000 63413406
Respiration abnormal 45.66 16.13 25 15591 6392 63467014
Pancreatitis acute 45.66 16.13 44 15572 27122 63446284
Abdominal pain 43.05 16.13 164 15452 293292 63180114
Constipation 42.76 16.13 137 15479 224806 63248600
Impaired gastric emptying 41.75 16.13 28 15588 10304 63463102
Cholecystitis 40.14 16.13 32 15584 15345 63458061
Systemic lupus erythematosus 39.94 16.13 3 15613 208915 63264491
Nasal congestion 37.62 16.13 62 15554 65598 63407808
Appetite disorder 37.40 16.13 23 15593 7298 63466108
Medullary thyroid cancer 37.04 16.13 9 15607 212 63473194
Pneumonia 36.72 16.13 35 15581 456732 63016674
Toxicity to various agents 36.68 16.13 8 15608 247242 63226164
Injection site extravasation 35.82 16.13 24 15592 8817 63464589
Synovitis 34.85 16.13 3 15613 186915 63286491
Increased appetite 33.96 16.13 24 15592 9606 63463800
Glossodynia 32.99 16.13 3 15613 178873 63294533
Asthma 32.19 16.13 86 15530 127475 63345931
Arthropathy 32.10 16.13 9 15607 234783 63238623
Gastrointestinal disorder 31.63 16.13 87 15529 131152 63342254
Treatment failure 30.42 16.13 6 15610 199037 63274369
Contraindicated product administered 30.39 16.13 8 15608 217640 63255766
Rales 30.14 16.13 25 15591 12672 63460734
Neutropenia 29.59 16.13 4 15612 175001 63298405
Rheumatoid arthritis 29.11 16.13 13 15603 253806 63219600
Illness 29.01 16.13 47 15569 49012 63424394
Death 28.56 16.13 30 15586 374351 63099055
Product use in unapproved indication 27.81 16.13 102 15514 178978 63294428
Irregular sleep phase 27.77 16.13 5 15611 24 63473382
Hunger 27.74 16.13 17 15599 5362 63468044
Obstructive pancreatitis 26.85 16.13 8 15608 415 63472991
Vision blurred 26.31 16.13 65 15551 91859 63381547
Drug hypersensitivity 25.89 16.13 23 15593 310664 63162742
Lactic acidosis 25.87 16.13 39 15577 38248 63435158
Maculopathy 25.42 16.13 12 15604 2250 63471156
Therapeutic product effect decreased 25.31 16.13 8 15608 193179 63280227
Joint swelling 25.28 16.13 26 15590 327640 63145766
Exposure during pregnancy 25.26 16.13 4 15612 155543 63317863
Blood glucose abnormal 24.04 16.13 18 15598 7874 63465532
Abdominal distension 23.48 16.13 60 15556 86555 63386851
Thrombocytopenia 22.18 16.13 5 15611 151152 63322254
Urethral caruncle 22.18 16.13 5 15611 84 63473322
Abdominal pain upper 22.16 16.13 105 15511 206339 63267067
Glomerular filtration rate decreased 21.14 16.13 21 15595 13420 63459986
Diabetes mellitus inadequate control 20.83 16.13 22 15594 15104 63458302
Urine calcium/creatinine ratio increased 20.69 16.13 5 15611 115 63473291
Counterfeit product administered 20.57 16.13 4 15612 31 63473375
Headache 20.19 16.13 241 15375 633000 62840406
Stomatitis 19.55 16.13 5 15611 138720 63334686
Productive cough 19.48 16.13 46 15570 63162 63410244
Angina pectoris 19.41 16.13 30 15586 30048 63443358
Dermatitis atopic 18.74 16.13 17 15599 9707 63463699
Diabetes mellitus 18.72 16.13 42 15574 55768 63417638
Product label confusion 18.45 16.13 9 15607 1813 63471593
Urinary incontinence 18.02 16.13 30 15586 31984 63441422
Contraindicated product prescribed 17.93 16.13 8 15608 1317 63472089
Infection 17.87 16.13 18 15598 229155 63244251
Incorrect dose administered 17.78 16.13 43 15573 59925 63413481
Blister 17.68 16.13 5 15611 129809 63343597
Blood creatine increased 17.56 16.13 13 15603 5588 63467818
Bile duct stone 17.45 16.13 11 15605 3645 63469761
Chronic kidney disease 17.33 16.13 36 15580 45362 63428044
Reperfusion arrhythmia 17.17 16.13 5 15611 239 63473167
Oedema peripheral 17.05 16.13 13 15603 189498 63283908
Discomfort 17.05 16.13 10 15606 167364 63306042
Product prescribing error 16.66 16.13 26 15590 26263 63447143
Food craving 16.46 16.13 8 15608 1598 63471808
Blood creatine phosphokinase increased 16.44 16.13 28 15588 30402 63443004
Infusion related reaction 16.22 16.13 22 15594 245499 63227907

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vomiting 536.11 20.37 482 9185 247139 34700125
Nausea 526.69 20.37 550 9117 339358 34607906
Pancreatitis 463.15 20.37 222 9445 38669 34908595
Diarrhoea 209.12 20.37 379 9288 389533 34557731
Euglycaemic diabetic ketoacidosis 176.93 20.37 56 9611 3166 34944098
Diabetic ketoacidosis 167.08 20.37 87 9580 17945 34929319
Eructation 122.74 20.37 47 9620 4684 34942580
Glycosylated haemoglobin increased 100.03 20.37 53 9614 11307 34935957
Weight decreased 91.85 20.37 170 9497 176131 34771133
Decreased appetite 88.62 20.37 162 9505 166230 34781034
Gastrointestinal disorder 86.32 20.37 73 9594 33875 34913389
Cholecystitis acute 83.23 20.37 39 9628 6400 34940864
Retinopathy 77.74 20.37 27 9640 2037 34945227
Abdominal pain 74.39 20.37 149 9518 163469 34783795
Blood glucose increased 68.18 20.37 88 9579 66630 34880634
Bile duct stone 64.68 20.37 25 9642 2552 34944712
Pancreatic carcinoma 63.10 20.37 36 9631 8865 34938399
Diabetic retinopathy 61.67 20.37 22 9645 1795 34945469
Constipation 60.12 20.37 123 9544 136859 34810405
Cholelithiasis 56.88 20.37 47 9620 21101 34926163
Pancreatitis acute 54.65 20.37 52 9615 28089 34919175
Abdominal discomfort 53.56 20.37 74 9593 59761 34887503
Vision blurred 52.30 20.37 64 9603 45899 34901365
Gastrooesophageal reflux disease 50.09 20.37 57 9610 37867 34909397
Obstructive pancreatitis 43.78 20.37 13 9654 591 34946673
Flatulence 42.74 20.37 40 9627 21158 34926106
Cholecystitis 42.52 20.37 30 9637 10658 34936606
Abdominal distension 41.71 20.37 65 9602 58427 34888837
Necrotising myositis 37.98 20.37 12 9655 673 34946591
Lipase increased 36.46 20.37 26 9641 9390 34937874
Dehydration 36.44 20.37 98 9569 129871 34817393
Ketoacidosis 35.10 20.37 19 9648 4224 34943040
Blood glucose decreased 34.71 20.37 29 9638 13208 34934056
Pneumonia 34.34 20.37 30 9637 362597 34584667
Abdominal pain upper 32.24 20.37 65 9602 71425 34875839
Drug dose titration not performed 32.10 20.37 9 9658 333 34946931
Inappropriate schedule of product administration 30.95 20.37 59 9608 62237 34885027
Neuropathy vitamin B12 deficiency 30.44 20.37 7 9660 114 34947150
Acute kidney injury 29.06 20.37 163 9504 304825 34642439
Dizziness 28.74 20.37 128 9539 218393 34728871
Gastric ischaemia 28.13 20.37 5 9662 19 34947245
Dyspepsia 27.83 20.37 42 9625 36690 34910574
Neutropenia 27.63 20.37 5 9662 156773 34790491
Febrile neutropenia 27.30 20.37 3 9664 136846 34810418
Impaired gastric emptying 27.28 20.37 15 9652 3438 34943826
Pharyngeal swelling 27.02 20.37 13 9654 2259 34945005
Dysmetria 26.94 20.37 9 9658 603 34946661
Vitreous haemorrhage 26.49 20.37 13 9654 2360 34944904
Glomerular filtration rate decreased 25.24 20.37 24 9643 12937 34934327
Medullary thyroid cancer 25.11 20.37 5 9662 39 34947225
Anaemia 24.97 20.37 17 9650 233318 34713946
Hiccups 24.21 20.37 21 9646 10061 34937203
Death 24.15 20.37 46 9621 398003 34549261
Vitamin B12 decreased 23.82 20.37 10 9657 1263 34946001
Hypoglycaemia 23.82 20.37 49 9618 54591 34892673
Therapeutic drug monitoring analysis incorrectly performed 23.52 20.37 7 9660 321 34946943
Diabetes mellitus inadequate control 22.62 20.37 23 9644 13441 34933823
Product communication issue 21.91 20.37 7 9660 407 34946857
Pancreatitis necrotising 21.84 20.37 12 9655 2746 34944518
Gait spastic 21.83 20.37 9 9658 1087 34946177
Product label confusion 21.35 20.37 6 9661 224 34947040
Lactic acidosis 21.18 20.37 36 9631 34736 34912528
General physical health deterioration 20.72 20.37 5 9662 128264 34819000

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nausea 614.87 15.41 955 19098 956241 78768094
Vomiting 583.09 15.41 771 19282 665057 79059278
Diabetic ketoacidosis 377.14 15.41 180 19873 33942 79690393
Pancreatitis 376.43 15.41 227 19826 68348 79655987
Euglycaemic diabetic ketoacidosis 308.19 15.41 100 19953 6744 79717591
Diarrhoea 215.12 15.41 592 19461 879897 78844438
Glycosylated haemoglobin increased 146.54 15.41 79 19974 19181 79705154
Decreased appetite 144.43 15.41 286 19767 342132 79382203
Weight decreased 140.67 15.41 289 19764 354909 79369426
Eructation 131.03 15.41 61 19992 10848 79713487
Blood glucose increased 114.84 15.41 143 19910 114832 79609503
Cholelithiasis 109.57 15.41 97 19956 52567 79671768
Cholecystitis acute 90.81 15.41 51 20002 13400 79710935
Abdominal pain 86.57 15.41 254 19799 389315 79335020
Pancreatitis acute 85.01 15.41 82 19971 49522 79674813
Heart sounds 81.92 15.41 23 20030 943 79723392
Sleep disorder due to a general medical condition 80.10 15.41 48 20005 14229 79710106
Bile duct stone 78.96 15.41 35 20018 5554 79718781
Pancreatic carcinoma 77.09 15.41 46 20007 13531 79710804
Prolonged expiration 75.68 15.41 23 20030 1248 79723087
COVID-19 74.00 15.41 138 19915 157536 79566799
Dehydration 73.42 15.41 180 19873 248007 79476328
Ketoacidosis 70.51 15.41 36 20017 7818 79716517
Constipation 67.10 15.41 189 19864 282861 79441474
Inappropriate schedule of product administration 65.26 15.41 119 19934 133509 79590826
Drug titration error 64.82 15.41 20 20033 1142 79723193
Lipase increased 61.81 15.41 43 20010 16423 79707912
Cholecystitis 60.88 15.41 48 20005 22164 79702171
Drug ineffective 59.38 15.41 114 19939 1080799 78643536
Drug dose titration not performed 58.43 15.41 17 20036 793 79723542
Blood glucose decreased 57.92 15.41 50 20003 26184 79698151
Diabetic retinopathy 55.59 15.41 23 20030 3083 79721252
Hypoglycaemia 54.12 15.41 94 19959 101500 79622835
Obstructive pancreatitis 52.54 15.41 16 20037 874 79723461
Flatulence 50.60 15.41 58 19995 42666 79681669
Pneumonia 50.57 15.41 55 19998 660191 79064144
Abdominal distension 50.32 15.41 100 19953 119550 79604785
Product communication issue 49.66 15.41 16 20037 1053 79723282
Flank pain 48.28 15.41 40 20013 19804 79704531
Neutropenia 46.84 15.41 8 20045 287702 79436633
Toxicity to various agents 46.52 15.41 24 20029 421516 79302819
Mesenteric panniculitis 45.94 15.41 12 20041 373 79723962
Depressive symptom 45.12 15.41 25 20028 6398 79717937
Abdominal pain upper 44.95 15.41 141 19912 223678 79500657
Vision blurred 41.54 15.41 86 19967 105812 79618523
Lactic acidosis 41.31 15.41 68 19985 70291 79654044
Retinopathy 38.35 15.41 19 20034 3872 79720463
Appetite disorder 38.25 15.41 24 20029 7715 79716620
Acute kidney injury 38.17 15.41 242 19811 519162 79205173
Respiration abnormal 38.11 15.41 24 20029 7764 79716571
Death 37.26 15.41 53 20000 566461 79157874
Asthma 36.76 15.41 95 19958 135000 79589335
Necrotising myositis 35.53 15.41 13 20040 1255 79723080
Diabetes mellitus inadequate control 34.02 15.41 36 20017 24228 79700107
Myoglobinuria 33.52 15.41 12 20041 1088 79723247
Nasal congestion 33.40 15.41 65 19988 76487 79647848
Dyspepsia 33.32 15.41 80 19973 108607 79615728
Neuropathy vitamin B12 deficiency 32.79 15.41 7 20046 88 79724247
Disease progression 32.61 15.41 4 20049 184358 79539977
Thrombocytopenia 32.52 15.41 13 20040 265246 79459089
Pancreatitis necrotising 32.45 15.41 17 20036 3891 79720444
Thyroid mass 32.12 15.41 17 20036 3973 79720362
Vitamin B12 decreased 31.27 15.41 16 20037 3489 79720846
Febrile neutropenia 30.55 15.41 10 20043 230989 79493346
Vitreous haemorrhage 30.40 15.41 16 20037 3697 79720638
Respiratory failure 29.49 15.41 5 20048 180906 79543429
Gastrooesophageal reflux disease 29.07 15.41 74 19979 104172 79620163
Gastric ischaemia 28.61 15.41 5 20048 19 79724316
Pancreatic carcinoma metastatic 27.44 15.41 15 20038 3738 79720597
Synovitis 27.33 15.41 3 20050 150731 79573604
Rales 26.85 15.41 29 20024 19972 79704363
Pancytopenia 26.11 15.41 5 20048 165740 79558595
Anaemia 26.02 15.41 45 20008 444970 79279365
General physical health deterioration 25.71 15.41 19 20034 275219 79449116
Glomerular filtration rate decreased 25.50 15.41 30 20023 22672 79701663
Medullary thyroid cancer 25.49 15.41 7 20046 264 79724071
Impaired gastric emptying 25.45 15.41 21 20032 10332 79714003
Malignant neoplasm progression 23.92 15.41 3 20050 135987 79588348
Pleural effusion 23.71 15.41 4 20049 145258 79579077
Therapeutic product effect decreased 23.68 15.41 6 20047 163857 79560478
Drug abuse 23.42 15.41 6 20047 162685 79561650
Hospitalisation 23.32 15.41 64 19989 94172 79630163
Off label use 23.31 15.41 338 19715 906877 78817458
Platelet count decreased 23.11 15.41 10 20043 194654 79529681
Arthropathy 22.84 15.41 8 20045 177103 79547232
Urethral caruncle 22.66 15.41 5 20048 74 79724261
Maculopathy 22.64 15.41 12 20041 2813 79721522
Product label confusion 22.38 15.41 10 20043 1616 79722719
Pharyngeal swelling 21.84 15.41 17 20036 7702 79716633
Dizziness 21.82 15.41 215 19838 526226 79198109
Drug hypersensitivity 21.63 15.41 26 20027 298890 79425445
Irregular sleep phase 21.44 15.41 5 20048 96 79724239
Rheumatoid arthritis 21.34 15.41 13 20040 208457 79515878
Blood glucose abnormal 21.04 15.41 19 20034 10547 79713788
Increased appetite 20.88 15.41 20 20033 11958 79712377
Injection site extravasation 20.47 15.41 18 20035 9651 79714684
Stomatitis 20.03 15.41 6 20047 146751 79577584
Joint swelling 19.95 15.41 26 20027 288620 79435715
Hyperglycaemia 19.67 15.41 50 20003 70285 79654050
Urine calcium/creatinine ratio increased 19.54 15.41 5 20048 143 79724192
Leukopenia 19.48 15.41 3 20050 116510 79607825
Food aversion 19.46 15.41 8 20045 1055 79723280
Somnolence 19.26 15.41 19 20034 238962 79485373
Food craving 19.07 15.41 9 20044 1648 79722687
Therapeutic drug monitoring analysis incorrectly performed 18.80 15.41 7 20046 709 79723626
Illness 18.49 15.41 38 20015 46473 79677862
Amylase increased 18.20 15.41 18 20035 11191 79713144
Weight loss poor 18.11 15.41 8 20045 1258 79723077
Bradycardia 17.69 15.41 6 20047 135551 79588784
Oedema peripheral 17.15 15.41 23 20030 252265 79472070
Intentional overdose 17.11 15.41 3 20050 105957 79618378
Treatment failure 16.93 15.41 11 20042 170475 79553860
Glossodynia 16.52 15.41 3 20050 103334 79621001
Chronic kidney disease 16.44 15.41 45 20008 66109 79658226
Cholecystitis chronic 16.25 15.41 16 20037 9890 79714445
Impaired quality of life 16.14 15.41 19 20034 14367 79709968
Allodynia 16.10 15.41 8 20045 1640 79722695
Reperfusion arrhythmia 16.05 15.41 5 20048 295 79724040
Incorrect dose administered 16.02 15.41 49 20004 76581 79647754
Contraindicated product administered 15.87 15.41 10 20043 157528 79566807
Cardiac failure congestive 15.84 15.41 8 20045 142394 79581941
Contraindicated product prescribed 15.77 15.41 8 20045 1713 79722622
Product dispensing error 15.69 15.41 18 20035 13245 79711090
Cardio-respiratory arrest 15.62 15.41 4 20049 108506 79615829
Infection 15.47 15.41 23 20030 241689 79482646

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BJ06 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glucagon-like peptide-1 (GLP-1) analogues
FDA CS M0160181 Glucagon-Like Peptide 1
FDA MoA N0000020058 Glucagon-like Peptide-1 (GLP-1) Agonists
FDA EPC N0000178480 GLP-1 Receptor Agonist
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:63726 neuroprotective agents
CHEBI has role CHEBI:71196 GLP-1 receptor agonist
CHEBI has role CHEBI:74518 anti-obestic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Weight loss indication 89362005
Obesity indication 414916001 DOID:9970




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.23 acidic
pKa2 3.31 acidic
pKa3 3.71 acidic
pKa4 3.97 acidic
pKa5 4.22 acidic
pKa6 4.53 acidic
pKa7 4.76 acidic
pKa8 9.65 acidic
pKa9 12.06 acidic
pKa10 12.28 acidic
pKa11 12.41 acidic
pKa12 12.5 acidic
pKa13 12.63 acidic
pKa14 12.76 acidic
pKa15 12.95 acidic
pKa16 12.98 acidic
pKa17 13.11 acidic
pKa18 13.18 acidic
pKa19 13.24 acidic
pKa20 13.3 acidic
pKa21 13.4 acidic
pKa22 13.51 acidic
pKa23 13.61 acidic
pKa24 13.66 acidic
pKa25 13.73 acidic
pKa26 13.77 acidic
pKa27 13.83 acidic
pKa28 13.87 acidic
pKa29 13.94 acidic
pKa30 11.05 Basic
pKa31 10.45 Basic
pKa32 7.88 Basic
pKa33 5.98 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
2MG/1.5ML (1.34MG/ML) OZEMPIC NOVO N209637 Dec. 5, 2017 RX SOLUTION SUBCUTANEOUS 8536122 March 20, 2026 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
2MG/3ML (0.68MG/ML) OZEMPIC NOVO N209637 Oct. 6, 2022 RX SOLUTION SUBCUTANEOUS 8536122 March 20, 2026 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
4MG/3ML (1.34MG/ML) OZEMPIC NOVO N209637 April 9, 2019 RX SOLUTION SUBCUTANEOUS 8536122 March 20, 2026 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
8MG/3ML (2.68MG/ML) OZEMPIC NOVO N209637 March 28, 2022 RX SOLUTION SUBCUTANEOUS 8536122 March 20, 2026 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8536122 March 20, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8536122 March 20, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8536122 March 20, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
2MG/1.5ML (1.34MG/ML) OZEMPIC NOVO N209637 Dec. 5, 2017 RX SOLUTION SUBCUTANEOUS 8129343 Dec. 5, 2031 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
2MG/3ML (0.68MG/ML) OZEMPIC NOVO N209637 Oct. 6, 2022 RX SOLUTION SUBCUTANEOUS 8129343 Dec. 5, 2031 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
4MG/3ML (1.34MG/ML) OZEMPIC NOVO N209637 April 9, 2019 RX SOLUTION SUBCUTANEOUS 8129343 Dec. 5, 2031 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
8MG/3ML (2.68MG/ML) OZEMPIC NOVO N209637 March 28, 2022 RX SOLUTION SUBCUTANEOUS 8129343 Dec. 5, 2031 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8129343 Dec. 5, 2031 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8129343 Dec. 5, 2031 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 8129343 Dec. 5, 2031 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 9278123 Dec. 16, 2031 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 9278123 Dec. 16, 2031 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 9278123 Dec. 16, 2031 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
2MG/1.5ML (1.34MG/ML) OZEMPIC NOVO N209637 Dec. 5, 2017 RX SOLUTION SUBCUTANEOUS 10335462 June 21, 2033 A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
2MG/3ML (0.68MG/ML) OZEMPIC NOVO N209637 Oct. 6, 2022 RX SOLUTION SUBCUTANEOUS 10335462 June 21, 2033 A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
4MG/3ML (1.34MG/ML) OZEMPIC NOVO N209637 April 9, 2019 RX SOLUTION SUBCUTANEOUS 10335462 June 21, 2033 A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
0.25MG/0.5ML (0.25MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 9764003 June 21, 2033 METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
0.5MG/0.5ML (0.5MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 9764003 June 21, 2033 METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
1.7MG/0.75ML (1.7MG/0.75ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 9764003 June 21, 2033 METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
1MG/0.5ML (1MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 9764003 June 21, 2033 METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
2.4MG/0.75ML (2.4MG/0.75ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 9764003 June 21, 2033 METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 10278923 May 2, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 10278923 May 2, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL 10278923 May 2, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS
0.25MG/0.5ML (0.25MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 10888605 Aug. 24, 2038 METHOD FOR WEIGHT MANAGEMENT
0.5MG/0.5ML (0.5MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 10888605 Aug. 24, 2038 METHOD FOR WEIGHT MANAGEMENT
1.7MG/0.75ML (1.7MG/0.75ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 10888605 Aug. 24, 2038 METHOD FOR WEIGHT MANAGEMENT
1MG/0.5ML (1MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 10888605 Aug. 24, 2038 METHOD FOR WEIGHT MANAGEMENT
2.4MG/0.75ML (2.4MG/0.75ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 10888605 Aug. 24, 2038 METHOD FOR WEIGHT MANAGEMENT
0.25MG/0.5ML (0.25MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 11318191 Feb. 17, 2041 METHOD FOR WEIGHT MANAGEMENT
0.5MG/0.5ML (0.5MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 11318191 Feb. 17, 2041 METHOD FOR WEIGHT MANAGEMENT
1.7MG/0.75ML (1.7MG/0.75ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 11318191 Feb. 17, 2041 METHOD FOR WEIGHT MANAGEMENT
1MG/0.5ML (1MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 11318191 Feb. 17, 2041 METHOD FOR WEIGHT MANAGEMENT
2.4MG/0.75ML (2.4MG/0.75ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS 11318191 Feb. 17, 2041 METHOD FOR WEIGHT MANAGEMENT

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
2MG/1.5ML (1.34MG/ML) OZEMPIC NOVO N209637 Dec. 5, 2017 RX SOLUTION SUBCUTANEOUS Jan. 16, 2023 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
4MG/3ML (1.34MG/ML) OZEMPIC NOVO N209637 April 9, 2019 RX SOLUTION SUBCUTANEOUS Jan. 16, 2023 REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
14MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Jan. 16, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
3MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Jan. 16, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
7MG RYBELSUS NOVO N213051 Sept. 20, 2019 RX TABLET ORAL Jan. 16, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
0.25MG/0.5ML (0.25MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS June 4, 2024 NEW PRODUCT
0.5MG/0.5ML (0.5MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS June 4, 2024 NEW PRODUCT
1.7MG/0.75ML (1.7MG/0.75ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS June 4, 2024 NEW PRODUCT
1MG/0.5ML (1MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS June 4, 2024 NEW PRODUCT
2.4MG/0.75ML (2.4MG/0.75ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS June 4, 2024 NEW PRODUCT
8MG/3ML (2.68MG/ML) OZEMPIC NOVO N209637 March 28, 2022 RX SOLUTION SUBCUTANEOUS March 28, 2025 ADDITION OF A 3RD MAINTENANCE DOSE OF SEMAGLUTIDE
0.25MG/0.5ML (0.25MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS Dec. 23, 2025 NEW PATIENT POPULATION
0.5MG/0.5ML (0.5MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS Dec. 23, 2025 NEW PATIENT POPULATION
1.7MG/0.75ML (1.7MG/0.75ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS Dec. 23, 2025 NEW PATIENT POPULATION
1MG/0.5ML (1MG/0.5ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS Dec. 23, 2025 NEW PATIENT POPULATION
2.4MG/0.75ML (2.4MG/0.75ML) WEGOVY NOVO N215256 June 4, 2021 RX SOLUTION SUBCUTANEOUS Dec. 23, 2025 NEW PATIENT POPULATION

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucagon-like peptide 1 receptor GPCR AGONIST IC50 9.42 SCIENTIFIC LITERATURE DRUG LABEL

External reference:

IDSource
53AXN4NNHX UNII
4037164 VANDF
C3885068 UMLSCUI
CHEBI:167574 CHEBI
CHEMBL2108724 ChEMBL_ID
56843331 PUBCHEM_CID
DB13928 DRUGBANK_ID
D10025 KEGG_DRUG
9113 INN_ID
9724 IUPHAR_LIGAND_ID
304634 MMSL
325192 MMSL
33346 MMSL
d08688 MMSL
017424 NDDF
764283003 SNOMEDCT_US
764284009 SNOMEDCT_US
1991302 RXNORM
C000591245 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4130 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 30 sections
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4130 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 30 sections
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4130 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 30 sections
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4132 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 30 sections
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4132 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 30 sections
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4132 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 30 sections
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4136 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 30 sections
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4136 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 30 sections
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4136 INJECTION, SOLUTION 1.34 mg SUBCUTANEOUS NDA 30 sections
Ozempic HUMAN PRESCRIPTION DRUG LABEL 1 0169-4181 INJECTION, SOLUTION 0.68 mg SUBCUTANEOUS NDA 30 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4303 TABLET 3 mg ORAL NDA 29 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4303 TABLET 3 mg ORAL NDA 29 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4303 TABLET 3 mg ORAL NDA 29 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4307 TABLET 7 mg ORAL NDA 29 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4307 TABLET 7 mg ORAL NDA 29 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4307 TABLET 7 mg ORAL NDA 29 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4314 TABLET 14 mg ORAL NDA 29 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4314 TABLET 14 mg ORAL NDA 29 sections
RYBELSUS HUMAN PRESCRIPTION DRUG LABEL 1 0169-4314 TABLET 14 mg ORAL NDA 29 sections
WEGOVY HUMAN PRESCRIPTION DRUG LABEL 1 0169-4501 INJECTION, SOLUTION 1 mg SUBCUTANEOUS NDA 32 sections
WEGOVY HUMAN PRESCRIPTION DRUG LABEL 1 0169-4501 INJECTION, SOLUTION 1 mg SUBCUTANEOUS NDA 32 sections
WEGOVY HUMAN PRESCRIPTION DRUG LABEL 1 0169-4501 INJECTION, SOLUTION 1 mg SUBCUTANEOUS NDA 32 sections
WEGOVY HUMAN PRESCRIPTION DRUG LABEL 1 0169-4505 INJECTION, SOLUTION 0.50 mg SUBCUTANEOUS NDA 32 sections
WEGOVY HUMAN PRESCRIPTION DRUG LABEL 1 0169-4505 INJECTION, SOLUTION 0.50 mg SUBCUTANEOUS NDA 32 sections
WEGOVY HUMAN PRESCRIPTION DRUG LABEL 1 0169-4505 INJECTION, SOLUTION 0.50 mg SUBCUTANEOUS NDA 32 sections
WEGOVY HUMAN PRESCRIPTION DRUG LABEL 1 0169-4517 INJECTION, SOLUTION 1.70 mg SUBCUTANEOUS NDA 32 sections
WEGOVY HUMAN PRESCRIPTION DRUG LABEL 1 0169-4517 INJECTION, SOLUTION 1.70 mg SUBCUTANEOUS NDA 32 sections
WEGOVY HUMAN PRESCRIPTION DRUG LABEL 1 0169-4517 INJECTION, SOLUTION 1.70 mg SUBCUTANEOUS NDA 32 sections
WEGOVY HUMAN PRESCRIPTION DRUG LABEL 1 0169-4524 INJECTION, SOLUTION 2.40 mg SUBCUTANEOUS NDA 32 sections
WEGOVY HUMAN PRESCRIPTION DRUG LABEL 1 0169-4524 INJECTION, SOLUTION 2.40 mg SUBCUTANEOUS NDA 32 sections